Clinical Trial Update: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating autologous mesenchymal stem cells for neuromyelitis optica spectrum disorders (Devic's syndrome).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Devic Disease
• Devic Neuromyelitis Optica
• Devic Syndrome
• Neuromyelitis Optica Spectrum Disorders

Drugs mentioned

• Autologous mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Devic's Syndrome, Devic's Neuromyelitis Optica | Phase 2 | Status: COMPLETED